Last Updated : March 5, 2020
Details
Generic Name:
etonogestrel
Project Status:
Withdrawn
Therapeutic Area:
Prevention of pregnancy
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0629-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the prevention of pregnancy as an open benefit without restrictions
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Prevention of pregnancy
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | August 16, 2019 |
| Patient group input closed | October 07, 2019 |
| Clarification: - No patient input submission received | |
| Submission received | September 26, 2019 |
| Submission accepted | October 10, 2019 |
| Review initiated | October 11, 2019 |
| Draft CADTH review report(s) sent to sponsor | January 03, 2020 |
| Comments from sponsor on draft CADTH review report(s) received | January 14, 2020 |
| CADTH review team's comments on draft CADTH review report(s) sent to sponsor | February 06, 2020 |
| Clarification: Withdrawn on 19 Feb 2020 | |
Last Updated : March 5, 2020